Search | Clinical Trials Finder

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 200 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Novartis Pharmaceuticals, New Jersey

Conditions: Stretch Marks, Striae Distensae, Cosmetic Appearance of Stretch Marks
Interventions: Placebo Vehicle Cream, Centella Asiatica Cream; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Actinic Keratoses
Interventions: imiquimod cream, 3.75%, Vehicle Cream; Drug
Lead sponsor: Actavis Mid-Atlantic LLC; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 19
States / cities: Birmingham, Alabama • Miami, Florida • Newnan, Georgia + 16 more

Conditions: Actinic Keratoses
Interventions: Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India; Drug
Lead sponsor: Encube Ethicals Pvt. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 7
States / cities: Bakersfield, California • Cerritos, California • Lauderdale Lakes, Florida + 3 more

Conditions: Pruritus, Atopic Dermatitis
Interventions: difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more

Conditions: Hemangioma
Interventions: PediaBerry; Drug
Lead sponsor: Gayle Gordillo; Other
Eligibility: 1 Month to 19 Weeks
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Indianapolis, Indiana • Columbus, Ohio

Conditions: Acne Vulgaris
Interventions: Methyl aminolevulinate (MAL) PDT; Drug
Lead sponsor: Photocure; Industry
Eligibility: 15 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: Naperville, Illinois • Albuquerque, New Mexico

Conditions: Pachyonychia Congenita
Interventions: 1% sirolimus cream (TD201 1%); Drug
Lead sponsor: TransDerm, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Atopic Dermatitis
Interventions: 1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2; Drug
Lead sponsor: Amytrx Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Cerritos, California • Encino, California • Long Beach, California + 8 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: MK-0873 2% Cream, MK-0873 vehicle (placebo) Cream, Calcitriol Cream; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Fort Myers, Florida • Miramar, Florida

Conditions: Vulvovaginal Candidiasis
Interventions: Butoconazole Nitrate Vaginal Cream, Placebo, Gynazole 1 vaginal cream; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 611 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 12 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 0
States / cities: Not listed

Conditions: Head Lice
Interventions: Ivermectin cream, vehicle control; Drug
Lead sponsor: Topaz Pharmaceuticals Inc; Industry
Eligibility: 2 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 12
States / cities: Yuma, Arizona • Los Angeles, California • Delray Beach, Florida + 9 more

Conditions: Head Lice
Interventions: 0.5% Ivermectin Cream, Placebo control; Drug
Lead sponsor: Topaz Pharmaceuticals Inc; Industry
Eligibility: 5 Months and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 7
States / cities: Little Rock, Arkansas • Delray Beach, Florida • St. Petersburg, Florida + 4 more

Conditions: Pilonidal Disease, Pilonidal Disease of Natal Cleft, Pilonidal Sinus, Pilonidal Cyst
Interventions: 1% Clascoterone, Vehicle Cream; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Interdigital Tinea Pedis
Interventions: Econazole Nitrate, placebo; Drug
Lead sponsor: AmDerma; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Epidermolysis Bullosa
Interventions: SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%); Drug
Lead sponsor: Scioderm, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 7
States / cities: Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more

Conditions: Chronic Hand Eczema
Interventions: ARQ-252 cream 0.3%, ARQ-252 cream 0.1%, ARQ-252 Vehicle Cream; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 25
States / cities: Beverly Hills, California • Encino, California • Fremont, California + 21 more

Conditions: Psoriasis Vulgaris, Topical Administration
Interventions: Total coumarin (TC) cream, Vehicle; Drug
Lead sponsor: Psoriasis Research Institute of Guangzhou; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: New York, New York • Seattle, Washington

Conditions: Acne Vulgaris
Interventions: Vehicle, Tazarotene Cream, 0.1 %, Tazorac Cream, 0.1%; Drug
Lead sponsor: G & W Laboratories Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,741 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Arlington Hts., Illinois

Conditions: Arthritis, Degenerative
Interventions: Experimental: 3VM1001 active 2g Cream 3 times daily, Experimental: 3VM1001 active 3g Cream 3 times daily, Experimental: 3VM1001 active 3g Cream 4 times daily, Placebo: 3VM1001 vehicle 2g Cream 3 times daily, Placebo: 3VM1001 vehicle 3g Cream 3 times daily, Placebo: 3VM1001 vehicle 3g Cream 4 times daily; Drug
Lead sponsor: CDA Research Group, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Atrophic Vaginitis
Interventions: Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 44
States / cities: Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more

Conditions: Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Skin Neoplasms, Skin Diseases, Neoplasms, Basal Cell, Neoplasms, Squamous Cell, Carcinoma
Interventions: 5-fluorouracil, Placebo, vehicle control; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 13
States / cities: Palo Alto, California • San Diego, California • Denver, Colorado + 10 more

Conditions: Acne Vulgaris
Interventions: Tazarotene Cream 0.1%, Tazorac®, Placebo; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 25
States / cities: Tucson, Arizona • Conway, Arkansas • Hot Springs, Arkansas + 20 more

Search by objective public record fields.

Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis

Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses

Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Natural Berry Extract Treatment of Hemangiomas

Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris

Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations

Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients

Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects

A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects

Topical Anti-Androgens in Pilonidal Sinus Disease

Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris

3VM for Treatment of Chronic Osteoarthritis Knee Pain

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris